These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 21990364)

  • 1. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
    Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
    J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
    Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
    J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
    Hashizume M; Mihara M
    Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.
    Lee SY; Buhimschi IA; Dulay AT; Ali UA; Zhao G; Abdel-Razeq SS; Bahtiyar MO; Thung SF; Funai EF; Buhimschi CS
    J Immunol; 2011 Mar; 186(5):3226-36. PubMed ID: 21282511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
    Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
    J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
    Rose-John S
    Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
    Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
    J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis.
    Sodenkamp J; Waetzig GH; Scheller J; Seegert D; Grötzinger J; Rose-John S; Ehlers S; Hölscher C
    Immunobiology; 2012 Oct; 217(10):996-1004. PubMed ID: 22387074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
    Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
    Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
    Sommer J; Garbers C; Wolf J; Trad A; Moll JM; Sack M; Fischer R; Grötzinger J; Waetzig GH; Floss DM; Scheller J
    J Biol Chem; 2014 Aug; 289(32):22140-50. PubMed ID: 24973212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.
    Prenissl N; Lokau J; Rose-John S; Haybaeck J; Garbers C
    Cytokine; 2019 Feb; 114():1-5. PubMed ID: 30557809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure.
    Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C
    J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T
    Heise D; Derrac Soria A; Hansen S; Dambietz C; Akbarzadeh M; Berg AF; Waetzig GH; Jones SA; Dvorsky R; Ahmadian MR; Scheller J; Moll JM
    Sci Signal; 2021 Aug; 14(696):. PubMed ID: 34404751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
    Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
    J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex.
    Lacroix M; Rousseau F; Guilhot F; Malinge P; Magistrelli G; Herren S; Jones SA; Jones GW; Scheller J; Lissilaa R; Kosco-Vilbois M; Johnson Z; Buatois V; Ferlin W
    J Biol Chem; 2015 Nov; 290(45):26943-26953. PubMed ID: 26363066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
    Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
    Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19.
    Rodríguez-Hernández MÁ; Carneros D; Núñez-Núñez M; Coca R; Baena R; López-Ruiz GM; Cano-Serrano ME; Martínez-Tellería A; Fuentes-López A; Praena-Fernandez JM; Garbers C; Hernández-Quero J; García F; Rose-John S; Bustos M
    Front Immunol; 2022; 13():891456. PubMed ID: 35634332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
    Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
    Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
    Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
    Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.